SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.77+3.2%1:57 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (7266)10/29/2002 12:08:02 PM
From: NeuroInvestment  Read Replies (1) of 52153
 
Yes, I am puzzled that the press coverage,. and NASD report, seem to have focused primarily on the fraudulent claims made to the clinical trial site, as if they were the victim. In fact, the Sterling 'report' not only created a false report of adverse events, it also delivered false claims regarding indiplon's patent protection and the terms of the inlicensing agreement with DOV. It was too far off to have been accidental. The real victims were not at the clinical trial site, the true victims were the investing public, those who acted on the basis of false information. And in that context, the NASD action was far too weak. ( I did send these sentiments along to the WSJ reporter, FWIW).

Harry Tracy

NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News